Baxter International Inc.
BAX
NYSE·Healthcare·Medical - Instruments & Supplies·Mkt cap $13.4B
$25.83
▲ +1.02%
P/E
-12.66
Mkt Cap
$13.4B
52-Wk Range
$15.73–$30.00
52-Week Range
$15.73 - $30.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 7.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Global distribution network
- Comprehensive medical technology portfolio
- Strong research and development capabilities
- Established relationships with healthcare providers
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Turning profitable
Aging global population
Value
Undervalued - trading well below Medical Devices peers
Momentum
Hot
+34.3% over 3m
Quality
Stable
Strong fundamentals
Dividend
Token
0.15% yield
Smart-money signal
Who's buying BAX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
JUL 30, 2026
Reported EPS of $0.56 vs $0.37 consensus (+52.8% surprise). Revenue of $3.0B vs $2.8B expected (+5.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+52.8%
Revenue trend · last 8Q
—
-29%
+5%
+4%
+5%
+8%
+3%
+5%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.7B
$2.8B
$2.6B
$2.8B
$2.8B
$3.0B
$2.7B
$3.0B
Margins · last 8Q
Gross
34.9%
Operating
-1.7%
Profit
4.3%
Wall Street consensus
6 analysts · 33% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
33%
Hold
67%
Sell
0%
Median Price Target
—
Latest: Citi · Jul 31, 2026
vs Industry
How BAX stacks vs Medical - Instruments & Supplies
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related